Trademark & IP NewsGlobal developments, with a trademark and brand focus.
Explore global trademark, brand protection and related intellectual property developments, selected by Liangma Legalmark Trademark Team and organised by topic and publication date.
Liangma Legalmark Trademark Team selects and explains industry developments. Event dates are stated in each article.
The China National Intellectual Property Administration announced on 10 month 21 day that the Fifteenth China International Patent Technology and Products Fair will be held from 11 month 6 day to 8 day, 2026, at the Taihu International Expo Center in Wuxi, Jiangsu, under the theme "Patents Link Innovation, Transformation Releases Value," with 2.2 square meters of exhibition space, 8 exhibition zones, and more than 40 events. This edition highlights transaction attributes and internationalization, and will launch the first intellectual property equity investment fund of 10 billion yuan at the prefecture-level city level nationwide.
Liangma Legalmark Trademark Team EditorialRead update ↗
On 14, 10, 2026, the Select Committee of the Administrative Council of the European Patent Organisation held its 36 meeting. According to the European Patent Office operational report, since the Unitary Patent system was launched in 6, 2023, approximately 10.8 ten thousand requests for unitary effect have been received, with an average processing time of less than 10 days; the adoption rate among patent proprietors within the EU is close to 44%, and nearly two-thirds of European SMEs seeking patent protection choose the Unitary Patent; the global adoption rate has risen to approximately 31%, higher than 28.7% in 2025 and 25.6% in 2024.
Liangma Legalmark Trademark Team EditorialRead update ↗
The Supreme People's Court (2024) Judgment No. 931 of the Supreme People's Court (Administrative) clearly establishes: in a drug patent linkage lawsuit, where the patentee amends the claims and the amendment is accepted by the China National Intellectual Property Administration, such that the amended claims no longer constitute the "relevant patent right" referred to in Article seventy-six, paragraph one of the Patent Law, and the generic drug applicant does not agree to use them as the basis for trial, the case loses its basis for continued trial—if it is a civil case, the claims are dismissed by judgment; if it is an administrative adjudication case, only the adjudication is revoked, without an order to re-decide.
Liangma Legalmark Trademark Team EditorialRead update ↗
In decision T 1254/24, the European Patent Office Board of Appeal dismissed the opponent's appeal and maintained European Patent No. 2 163 423. In its interpretation of feature M 9 of claim 1, the Board held that the slot must be formed in the rigid shell rather than in the cover, and on that basis found the patent novel over the Apollo and Odyssey seats and document D 1.
Liangma Legalmark Trademark Team EditorialRead update ↗
